Key Highlights

● SeaStar Medical secured dedicated hospital billing codes for its pediatric kidney-injury device and posted 69% quarterly revenue growth, but the company remains pre-revenue in its larger adult market and is burning cash faster than sales are arriving.

● SeaStar ended the first quarter of 2026 with $9.3 million in cash, down from $12.0 million at year-end 2025, after using roughly $2.6 million to $2.8 million in operating cash.

● SeaStar remains far from self-sustaining: quarterly revenue of $0.5 million compares with a $3.5 million quarterly net loss, and full-year 2026 guidance is roughly $2 million in revenue.

● Investors should watch for second-quarter 2026 results, expected around August 13, 2026, for continued revenue growth.

SeaStar Medical Holding Corporation (Nasdaq: ICU), a Denver-based medical device company, told investors on June 23, 2026 that the Centers for Medicare & Medicaid Services has granted dedicated ICD-10-PCS billing codes for its Selective Cytopheretic Device (SCD) therapy, effective October 1, 2026. The codes formalize inpatient hospital billing for QUELIMMUNE, SeaStar's pediatric acute kidney injury (AKI) therapy, and management says they could also smooth a future launch in the far larger adult AKI market. The announcement followed a first-quarter update in which the company reported net revenue of $0.5 million, up 69% from a year earlier, alongside a widening customer base of pediatric hospitals and continued enrollment in its pivotal adult trial.

What happened

On June 23, 2026, SeaStar disclosed that CMS assigned new ICD-10-PCS codes covering SCD therapy for AKI patients requiring renal replacement therapy, to take effect at the start of the government's next fiscal year on October 1, 2026. Tim Varacek, SeaStar's senior vice president of commercial and business operations, said the codes would "ease the logistics for our existing QUELIMMUNE customers" and carry "significant implications for the potential launch of our SCD therapy in the adult AKI indication." The news came roughly six weeks after SeaStar's May 13, 2026 first-quarter report, which showed revenue climbing 69% year-over-year to $0.5 million, a net loss of $3.5 million, and a cash balance of $9.3 million as of March 31, 2026, down from $12.0 million at the end of 2025.

Why the development matters

Dedicated billing codes remove a documented friction point for hospitals seeking reimbursement for a novel therapy, and their timing coincides with SeaStar's ambition to expand SCD therapy beyond pediatrics. Management estimates the adult AKI market at roughly $4.5 billion and more than 200,000 patients annually, about 50 times the pediatric opportunity the company currently serves. However, the codes do not take effect until October 2026, and adult-indication revenue remains contingent on an ongoing pivotal trial and subsequent FDA review, so the near-term impact is likely administrative rather than immediately revenue-generating.

Company and product background

SeaStar's core product, the Selective Cytopheretic Device, is an extracorporeal blood-filtering therapy intended to modulate an overactive immune response in critically ill patients with AKI. The pediatric version, QUELIMMUNE, received FDA approval under a Humanitarian Device Exemption in February 2024 for critically ill pediatric patients weighing at least 10 kilograms with AKI and sepsis requiring renal replacement therapy. As of the first-quarter 2026 report, QUELIMMUNE was in use at 17 pediatric hospitals, up from 16 at year-end 2025, with management guiding to more than 15 additional hospital sites in 2026 and roughly $2 million in full-year net product revenue.

Financial position

SeaStar ended the first quarter of 2026 with $9.3 million in cash, down from $12.0 million at year-end 2025, after using roughly $2.6 million to $2.8 million in operating cash during the quarter. For full-year 2025, the company reported revenue of $1.2 million (versus $135,000 in 2024), a net loss of $12.2 million, and operating cash burn of $13.6 million, offset by $23.8 million raised during the year through equity issuances ($16.1 million), warrant exercises ($1.8 million), pre-funded warrants ($5.9 million) and notes payable ($767,000). SeaStar carried roughly $525,000 in notes payable, net of deferred financing costs, at year-end 2025. The company also effected a reverse stock split in December 2025 per an SEC filing; share counts cited across sources for year-end 2025 vary depending on whether they are split-adjusted, and shares outstanding stood at approximately 4.0 million as of March 31, 2026. At the recent burn rate and absent further financing, the $9.3 million cash balance implies a runway of roughly three to four quarters, an estimate, not a company disclosure.

Bull case

Bulls point to accelerating, if still small, commercial revenue, up 69% in the first quarter, alongside a widening hospital base and newly formalized billing infrastructure that could lower adoption barriers. If NEUTRALIZE-AKI completes enrollment on schedule and supports a PMA filing, SeaStar would gain access to an adult AKI market that management sizes at roughly $4.5 billion, dwarfing its current pediatric footprint. The company enters this stretch with a recapitalized balance sheet following $23.8 million raised in 2025.

Risk case

Bears note SeaStar remains far from self-sustaining: quarterly revenue of $0.5 million compares with a $3.5 million quarterly net loss, and full-year 2026 guidance of roughly $2 million would still leave the company deeply unprofitable. Cash of $9.3 million at quarter-end, against a multi-million-dollar quarterly burn, points to a limited runway and likely further dilution or financing. The adult indication depends on a trial only 58% enrolled as of the first quarter, with completion targeted for year-end 2026 and FDA review to follow, meaning any adult-market revenue is likely years away and unconfirmed by regulatory approval.

What investors should watch next

Investors can track: second-quarter 2026 results, expected around August 13, 2026, for continued revenue growth and hospital additions; NEUTRALIZE-AKI enrollment progress toward its 339-patient target, targeted for completion around year-end 2026; the October 1, 2026 effective date of the new ICD-10-PCS codes and whether hospital adoption or billing efficiency measurably improves afterward; initiation of modular PMA submissions for the adult AKI indication; and the pace of cash burn relative to the $9.3 million balance reported at the end of the first quarter, which will signal the timing of any future financing.

Conclusion

SeaStar Medical's new billing codes and 69% quarterly revenue growth mark incremental progress in commercializing QUELIMMUNE and in laying groundwork for a much larger adult AKI opportunity. But the company remains a small-revenue, cash-burning developmental medtech name whose adult-market ambitions hinge on a pivotal trial still enrolling patients and a regulatory pathway that has not yet begun. Investors weighing the stock face a straightforward tension between real, if modest, commercial traction and a balance sheet that will likely require further capital before the larger opportunity can be tested.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.